4.95
Bluebird Bio Inc Aktie (BLUE) Neueste Nachrichten
Deal Dispatch: US M&A Is Quiet, But Abroad? Volume Is Spiking - Benzinga
Gene Therapy Market Demand, Growth and Future Scope 2025-2032 | - openPR.com
Xcellbio Granted Bluebird Bio Commercial License, Got Into Supply Agreement For Use Of Co's Proprietary Cell Manufacturing Technology, Avatar - MarketScreener
Xcellbio Announces Commercial Licensing & Supply Agreement to Support Commercial Production of Gene Therapy for Sickle Cell disease - Business Wire
BlueBird Shares Are Up Today: What's Going On? - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumpsbluebird bio (NASDAQ:BLUE) - Benzinga
Bluebird Bio Receives $4.50 Per Share Acquisition Proposal From Ayrmid - Nasdaq
bluebird bio’s SWOT analysis: biotech firm’s stock faces cash crunch, product potential - Investing.com
Bluebird bio rises on non-binding bid for up to $110.5 million - TradingView
Bluebird bio receives non-binding bid for up to $110.5 million - MSN
Bluebird Bio (BLUE) Reports Q4 Loss, Tops Revenue Estimates - MSN
Key deals this week: xAI acquires X; bluebird bio, Nvidia, Dollar Tree and more - MSN
Key deals this week: xAI acquires X; bluebird bio, Nvidia, Dollar Tree and more (T:NYSE) - Seeking Alpha
bluebird bio confirms rival takeover bid - The Pharma Letter
Bluebird Bio Stock Leaps On Ayrmid Offer Amid Financial Strain - Finimize
Bluebird Bio Draws New Bid, Sending Shares Climbing - Finimize
Ayrmid Proposes to Acquire Bluebird Bio, Inc. (BLUE) with Premiu - GuruFocus
New suitor emerges for struggling bluebird bio - FirstWord Pharma
Bluebird Bio (BLUE) Receives Acquisition Offer from Ayrmid - GuruFocus.com
Bluebird bio receives rival M&A bid worth 50% higher than Carlyle-SK offer - Fierce Pharma
bluebird bio (BLUE) Receives Higher Bid from Ayrmid Pharma - GuruFocus
bluebird bio sees higher offer for company from Ayrmid Pharma - Seeking Alpha
Bluebird Bio (BLUE) Receives Higher Buyout Bid from Ayrmid - GuruFocus
Bluebird gets rival takeout offer from Ayrmid - BioPharma Dive
bluebird bio receives higher acquisition offer from Ayrmid - Investing.com India
Bluebird Bio shares rally 11% in late trade on buyout offer - TradingView
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
bluebird bio receives higher acquisition offer from Ayrmid By Investing.com - Investing.com South Africa
Bluebird bio reports another acquisition offer for $45M upfront - The Business Journals
Bluebird Bio Gets Rival Buyout Proposal From Ayrmid; Shares Jump After Hours - Marketscreener.com
Bluebird bio stock rises on new acquisition proposal By Investing.com - Investing.com South Africa
Bluebird bio stock rises on new acquisition proposal - Investing.com
Bluebird Bio confirms receipt non-binding proposal from Ayrmid - TipRanks
Bluebird Bio Confirms Receipt Of An Unsolicited Non-Binding Proposal From Ayrmid - Marketscreener.com
bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid - Business Wire
Sickle Cell Treatment Market Business Outlook and Growth - openPR
bluebird bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
T-Cell Immunotherapy Market is Booming Worldwide |Medigene,Bluebird Bio,Novartis - openPR
Sickle Cell Disease Treatment Market: New Drug Approvals - openPR
Breaking Notice: Rosen, a Globally Recognized Law Firm, Encourages bluebird bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline – BLUE - Business Wire
Gene therapy loses luster as investors eye quicker returns from weight-loss drugs - Reuters
Drug developers show mixed performance in early 2025 - BioWorld Online
Sickle Cell Disease Pipeline 2025 Detailed Clinical Trials - openPR
Carlyle's bluebird Deep Discount Buyout (Rating Upgrade) - Seeking Alpha
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc.BLUE - PR Newswire
Gene therapy efforts active, despite low Bluebird, 2seventy bids - BioWorld Online
BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc.BLUE - Business Wire
Gene Therapy Market Future Business Opportunities 2025-2032 | - openPR
Bristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio In $286M Deal - Dealbreaker
Bluebird’s Go-Private Deal Highlights Fraught Life Preserver for Struggling Biotechs - BioSpace
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):